Shattuck Labs, Inc. (NASDAQ:STTK) Stock Position Lifted by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 83.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 392,010 shares of the company’s stock after purchasing an additional 177,910 shares during the quarter. Renaissance Technologies LLC owned about 0.82% of Shattuck Labs worth $1,513,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of STTK. Dimensional Fund Advisors LP raised its position in shares of Shattuck Labs by 8.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock worth $266,000 after buying an additional 5,397 shares in the last quarter. American Century Companies Inc. raised its holdings in Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock worth $183,000 after purchasing an additional 9,608 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Shattuck Labs in the second quarter worth approximately $170,000. Rhumbline Advisers bought a new position in Shattuck Labs during the 2nd quarter valued at $182,000. Finally, Ritholtz Wealth Management increased its position in shares of Shattuck Labs by 57.4% during the 2nd quarter. Ritholtz Wealth Management now owns 142,540 shares of the company’s stock valued at $550,000 after purchasing an additional 52,000 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. BTIG Research lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a report on Monday, June 17th. Needham & Company LLC downgraded shares of Shattuck Labs from a “buy” rating to a “hold” rating and set a $8.00 price target for the company. in a report on Wednesday. HC Wainwright cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Tuesday. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Wednesday. Finally, Citigroup lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $8.00 to $2.00 in a research report on Wednesday. Four analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.67.

Shattuck Labs Trading Down 4.7 %

NASDAQ STTK opened at $1.22 on Friday. Shattuck Labs, Inc. has a 1 year low of $1.15 and a 1 year high of $11.76. The company has a market cap of $58.01 million, a PE ratio of -0.63 and a beta of 1.72. The stock’s 50-day moving average price is $3.43 and its two-hundred day moving average price is $6.01.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.50 million. The business’s quarterly revenue was up 704.5% compared to the same quarter last year. Research analysts forecast that Shattuck Labs, Inc. will post -1.72 EPS for the current fiscal year.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.